🇺🇸 BARICITINIB in United States

1,652 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 379 reports (22.94%)
  2. Drug Ineffective — 295 reports (17.86%)
  3. Pulmonary Embolism — 168 reports (10.17%)
  4. Covid-19 — 165 reports (9.99%)
  5. Pneumonia — 125 reports (7.57%)
  6. Rheumatoid Arthritis — 123 reports (7.45%)
  7. Deep Vein Thrombosis — 122 reports (7.38%)
  8. Death — 105 reports (6.36%)
  9. Drug Ineffective For Unapproved Indication — 86 reports (5.21%)
  10. Condition Aggravated — 84 reports (5.08%)

Source database →

BARICITINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is BARICITINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BARICITINIB in United States?

Marketing authorisation holder not available in our data.